Clinical Trial: A Multicenter, Single-Arm, Phase II Clinical Study Evaluating the Efficacy and Safety of Mannatide Combined with CAPOX and Tislelizumab as First-Line Treatment for Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (China)

China, Sept. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Multicenter, Single-Arm, Phase II Clinical Study Evaluating the Efficacy and Safety of Mannatide Combined with CAPOX and Tislelizumab as First-Line Treatment for Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132223

Registration Time: 2026/09/10

Type: Interventional study

Primary Sponsor: West China Hospital of Sichuan University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=331577

Published by HT Digital Content Services with permission from Health Daily Digest....